TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of “Hold” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has received an average rating of “Hold” from the thirteen brokerages that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $134.50.

Several analysts have recently commented on the company. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. TD Cowen lowered their price objective on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Needham & Company LLC lowered their price objective on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th.

TransMedics Group Stock Down 12.0%

TMDX stock opened at $68.44 on Friday. The stock’s 50 day simple moving average is $79.48 and its 200 day simple moving average is $110.46. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The company has a market cap of $2.37 billion, a P/E ratio of 15.55 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. During the same period last year, the company posted $0.70 earnings per share. The firm’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, research analysts expect that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group during the 3rd quarter valued at about $29,000. Optiver Holding B.V. grew its holdings in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after buying an additional 191 shares in the last quarter. North Star Investment Management Corp. bought a new position in TransMedics Group in the 1st quarter worth about $30,000. Ascentis Independent Advisors bought a new position in TransMedics Group in the 1st quarter worth about $30,000. Finally, Allworth Financial LP lifted its stake in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.